Kane Biotech Inc. has announced a significant change in the U.S. distribution of its revyve™ Antimicrobial Wound Gel. BioStem Technologies Inc. has signed a Letter of Intent to acquire exclusive U.S. distribution rights for revyve™ from the current distributor, ProgenaCare Global LLC.
Key Details:
- BioStem’s Strategic Move: This acquisition aligns with BioStem’s strategy to diversify its wound care product portfolio, leveraging its existing commercial infrastructure to enhance market presence. CEO Jason Matuszewski highlighted that revyve™ allows BioStem to address wounds earlier in the treatment continuum, broadening patient support and expanding distribution channels.
- Kane Biotech’s Perspective: Marc Edwards, President & CEO of Kane Biotech, expressed optimism about the partnership, citing BioStem’s impressive growth in the wound care sector as a catalyst for expanding revyve™’s market penetration in the U.S.
- Next Steps: BioStem aims to finalize definitive agreements within 60 days, pending customary due diligence, regulatory approvals, and Board consent. During this period, BioStem and ProgenaCare will collaborate to integrate revyve™ into BioStem’s product lineup.
About the Companies:
- BioStem Technologies: A leader in regenerative therapies, BioStem focuses on developing, manufacturing, and commercializing allografts derived from perinatal tissue. Their proprietary BioREtain® processing method emphasizes maintaining growth factors and preserving tissue structure. The company’s quality management system is accredited by the American Association of Tissue Banks (AATB).
- ProgenaCare Global LLC: A medical device company dedicated to providing effective and affordable advanced wound care solutions, ProgenaCare leverages cutting-edge biomaterials and medical device technologies to serve patients across various socioeconomic backgrounds worldwide.
- Kane Biotech Inc.: Specializing in technologies that prevent and remove microbial biofilms, Kane Biotech holds a portfolio of 66 patents and patents pending. Their products, including revyve™, are developed through in-house research and collaborations with leading institutions.
This strategic shift in distribution is poised to enhance the availability and reach of revyve™ Antimicrobial Wound Gel in the U.S. market, benefiting healthcare providers and patients alike.
